Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kazumi Kurishita
Institution:
National Cancer Centre Japan
Observed institutions:
National Cancer Centre Japan,
National Cancer Center Hospital
ORCID:
0009-0009-8830-145X
Observed ORCID:
0009-0009-8830-145X
OpenAlex ID:
A5002140240
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
2022
·
Yohei Chiba
, Kazuki Sudo
, et al.
·
BMC Cancer
·
8
PDF
Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003).
2025
·
Hitomi Sumiyoshi Okuma
, Ayumu Arakawa
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Safety and efficacy of the EZH1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): A multicenter phase I trial.
2025
·
Ayumu Arakawa
, Kanako Kondo
, et al.
·
Journal of Clinical Oncology
·
2
A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
2025
·
Junichi Matsubara
, Kazuki Sudo
, et al.
·
Journal of Clinical Oncology
·
2
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)
2026
·
Hitomi S. Okuma
, Ayumu Arakawa
, et al.
·
Clinical Cancer Research
·
1
PDF
10011-CS-2 A Phase II basket trial evaluating the efficacy of tasurgratinib in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration (FORTUNE study)
2025
·
Masamichi Takahashi
, Kazuki Sudo
, et al.
·
Neuro-Oncology Advances
PDF
Ctni-26. Results of a Multicenter Phase 2 Basket Trial Evaluating the Efficacy of Tasurgratinib (e7090) in Patients With Advanced Solid Tumors With Fibroblast Growth Factor Receptor (fgfr) Gene Alteration, Including Those With Primary Brain Tumors: Fortune Study
2025
·
Masamichi Takahashi
, Kazuki Sudo
, et al.
·
Neuro-Oncology
PDF
The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).
2025
·
Dai Ogata
, Eiji Nakano
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
8
Citation count:
16
H-index:
2
I10-index:
Year
Topic
Type